Article

Saving the Best for Last

Deepali Sachdev, PhD, and Hua Zhang, PhD, from the University of Minnesota showed in laboratory tests that IGF1-R inhibitors can help prevent metastases from developing, but do not have a big effect on metastases once they have developed. In another series of experiments, these inhibitors were shown to reverse resistance to the hormonal therapy Faslodex. While these drugs are in very early trials for a variety of cancers, one of their uses may be to combine them with other targeted drugs or hormonal therapy—ultimately large randomized studies will be needed to prove or disprove their utility.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
Image of woman.
Picture of Dr. Pouneh Razavi
Image of a woman wearing a headband and glasses
Image of doctor.
Image of woman.
Image of Doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.